SG11202101014XA - Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof - Google Patents
Chimeric antigen receptor therapy t cell expansion kinetics and uses thereofInfo
- Publication number
- SG11202101014XA SG11202101014XA SG11202101014XA SG11202101014XA SG11202101014XA SG 11202101014X A SG11202101014X A SG 11202101014XA SG 11202101014X A SG11202101014X A SG 11202101014XA SG 11202101014X A SG11202101014X A SG 11202101014XA SG 11202101014X A SG11202101014X A SG 11202101014XA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen receptor
- chimeric antigen
- cell expansion
- receptor therapy
- expansion kinetics
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 230000010261 cell growth Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862713994P | 2018-08-02 | 2018-08-02 | |
US201862756391P | 2018-11-06 | 2018-11-06 | |
PCT/US2019/044638 WO2020028647A1 (fr) | 2018-08-02 | 2019-08-01 | Cinétique d'expansion de lymphocytes t pour thérapie par récepteur d'antigène chimérique et ses utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101014XA true SG11202101014XA (en) | 2021-02-25 |
Family
ID=67770563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101014XA SG11202101014XA (en) | 2018-08-02 | 2019-08-01 | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200038442A1 (fr) |
EP (1) | EP3830125A1 (fr) |
JP (2) | JP2021531813A (fr) |
KR (1) | KR20210038922A (fr) |
CN (1) | CN112533953A (fr) |
AU (2) | AU2019314452B2 (fr) |
CA (2) | CA3170491A1 (fr) |
IL (1) | IL280329B1 (fr) |
SG (1) | SG11202101014XA (fr) |
TW (2) | TWI807077B (fr) |
WO (1) | WO2020028647A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202144400A (zh) * | 2020-02-20 | 2021-12-01 | 美商凱特製藥公司 | 嵌合抗原受體t細胞療法 |
CA3234494A1 (fr) * | 2021-10-15 | 2023-04-20 | Astrazeneca Ab | Recepteurs antigeniques chimeriques anti-steap2 et leurs utilisations |
WO2023159001A1 (fr) * | 2022-02-15 | 2023-08-24 | Kite Pharma, Inc. | Prédiction d'événements indésirables à partir d'une immunothérapie |
WO2024092145A1 (fr) * | 2022-10-28 | 2024-05-02 | Kite Pharma, Inc. | Administration accélérée de lymphocytes modifiés |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
JP2004500095A (ja) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | 細胞の同時の刺激および濃縮 |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
EP3305798A1 (fr) | 2010-12-09 | 2018-04-11 | The Trustees of The University of Pennsylvania | Utilisation de cellules t de récepteur modifié d'antigène chimérique pour traiter le cancer |
CA2824997C (fr) | 2011-01-18 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | Compositions et procedes de traitement du cancer |
CN106074601A (zh) | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
EP2532740A1 (fr) | 2011-06-11 | 2012-12-12 | Michael Schmück | Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif |
KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
WO2014055657A1 (fr) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Utilisation d'une approche trans-signalisation dans des récepteurs d'antigènes chimériques |
KR20220119176A (ko) * | 2014-02-04 | 2022-08-26 | 카이트 파마 인코포레이티드 | B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법 |
WO2015142661A1 (fr) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Récepteur d'antigène chimèrique régulable |
AU2015361261B2 (en) * | 2014-12-08 | 2020-03-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD70 chimeric antigen receptors |
WO2016130598A1 (fr) * | 2015-02-09 | 2016-08-18 | University Of Florida Research Foundation, Inc. | Récepteur antigénique chimérique bispécifique et ses utilisations |
JP2018513216A (ja) * | 2015-04-15 | 2018-05-24 | プロスペクト チャーターケア アールダブリュエムシー,エルエルシー ディ/ビー/エイ ロジャー ウィリアムズ メディカル センターProspect Chartercare Rwmc,Llc D/B/A Roger Williams Medical Center | Car−t細胞の肝動脈注入 |
WO2017015427A1 (fr) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Méthodes pour améliorer l'efficacité et l'expansion de cellules immunitaires |
CN110494451B (zh) * | 2017-01-13 | 2023-12-01 | 塞尔达拉医疗有限责任公司 | 靶向tim-1的嵌合抗原受体 |
-
2019
- 2019-08-01 SG SG11202101014XA patent/SG11202101014XA/en unknown
- 2019-08-01 JP JP2021505310A patent/JP2021531813A/ja active Pending
- 2019-08-01 EP EP19759453.4A patent/EP3830125A1/fr active Pending
- 2019-08-01 WO PCT/US2019/044638 patent/WO2020028647A1/fr unknown
- 2019-08-01 CA CA3170491A patent/CA3170491A1/fr active Pending
- 2019-08-01 KR KR1020217005607A patent/KR20210038922A/ko not_active IP Right Cessation
- 2019-08-01 CA CA3107938A patent/CA3107938C/fr active Active
- 2019-08-01 IL IL280329A patent/IL280329B1/en unknown
- 2019-08-01 AU AU2019314452A patent/AU2019314452B2/en active Active
- 2019-08-01 CN CN201980051623.2A patent/CN112533953A/zh active Pending
- 2019-08-01 US US16/529,081 patent/US20200038442A1/en active Pending
- 2019-08-02 TW TW108127613A patent/TWI807077B/zh active
- 2019-08-02 TW TW110134283A patent/TW202216175A/zh unknown
-
2023
- 2023-03-02 AU AU2023201286A patent/AU2023201286A1/en active Pending
- 2023-11-08 JP JP2023190807A patent/JP2024016200A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TWI807077B (zh) | 2023-07-01 |
EP3830125A1 (fr) | 2021-06-09 |
CA3107938A1 (fr) | 2020-02-06 |
IL280329B1 (en) | 2024-05-01 |
CN112533953A (zh) | 2021-03-19 |
JP2021531813A (ja) | 2021-11-25 |
AU2019314452A1 (en) | 2021-02-18 |
TW202216175A (zh) | 2022-05-01 |
WO2020028647A1 (fr) | 2020-02-06 |
JP2024016200A (ja) | 2024-02-06 |
TW202019445A (zh) | 2020-06-01 |
AU2023201286A1 (en) | 2023-04-06 |
IL280329A (en) | 2021-03-01 |
CA3107938C (fr) | 2024-04-30 |
US20200038442A1 (en) | 2020-02-06 |
AU2019314452B2 (en) | 2022-12-08 |
CA3170491A1 (fr) | 2020-02-06 |
KR20210038922A (ko) | 2021-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274921A (en) | BCMA-directed chimeric antigen receptor and uses thereof | |
IL280718A (en) | T cell structures and their uses | |
IL280329A (en) | Treatment with receptor-antigen chimeric kinetics of T cell expansion and their uses | |
IL274617A (en) | Chimeric antigen receptor-directed BCMA, chimeric antigen receptor-directed CD19, and combination therapies | |
SG10202012157QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
EP3564266A4 (fr) | Nouveau récepteur chimère de l'antigène et utilisation correspondante | |
EP3630980A4 (fr) | Préparation cellulaire de récepteurs antigéniques chimériques et utilisations de celle-ci | |
IL279063A (en) | Chimeric antigen receptor T cells for cancer therapy | |
ZA202000852B (en) | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof | |
IL271751A (en) | T cell receptors and immunotherapy using them | |
IL280029A (en) | ROR-1 specific chimeric antigen receptors and their uses | |
EP4045539A4 (fr) | Récepteur antigénique chimérique amélioré pour l'ingénierie de cellules effectrices immunitaires et son utilisation | |
SG11202010642TA (en) | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor | |
SG11202101169PA (en) | Chimeric antigen receptor that binds hla-dr and car-t cell | |
EP3827025A4 (fr) | Récepteur antigénique chimérique à base de gd2 et utilisation associée | |
EP3733839A4 (fr) | Cellule t modifiée par récepteur d'antigène chimère modifié par anticorps et leurs utilisations | |
IL281232A (en) | Chimeric antigen receptor for solid cancer and t cells expressing chimeric antigen receptor | |
ZA201906321B (en) | Chimeric antigen receptor | |
EP3573660A4 (fr) | Constructions améliorées de récepteur de lymphocytes t couplé à un anticorps et leurs utilisations thérapeutiques | |
IL281428A (en) | chimeric antigen receptor | |
IL308227A (en) | T-cell chemical antigen receptor therapy | |
SG11202001011XA (en) | Chimeric antigen receptor and car-t cells that bind cxcr5 | |
EP4105240A4 (fr) | Récepteur antigénique chimérique et son utilisation | |
GB201709508D0 (en) | Chimeric antigen receptor | |
GB2585607B (en) | Chimeric antigen receptor and application thereof |